Dr. Hak Choy, MD

In the course of more than 30 years as a radiation oncologist, Hak Choy, M.D., has worked with almost every new compound that has been developed to combine with radiation, and has distinguished himself as a world-leading expert in chemoradiation therapy. Dr. Choy is Professor and Chair of the Department of Radiation Oncology at UT Southwestern and holds the Nancy B. and Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research. He graduated from the University of Texas Medical Branch in Galveston and completed a residency in Internal Medicine/Radiation Oncology at Ohio State, as well as a residency in Radiation Oncology at the University of Texas Health Science Center in San Antonio. Dr. Choy is board certified in Therapeutic Radiology and was Professor and Vice Chair of the Department of Radiation Oncology at Vanderbilt University before joining UT Southwestern as department chair in 2003. He has been the prime motivator in growing UT Southwesterns radiation oncology …practice to the regions largest, with two campus locations, including one that opened in 2011. Dr. Choy is active in the clinic, where he treats patients presenting with small cell lung cancer, non-small cell lung cancer, and metastases of lung cancer to other sites. He continues to be a lead investigator of clinical trials offering new combinations of treatments to patients. Dr. Choy currently serves as Chair of the Data Safety Monitoring Board and Vice Chair of the Executive Committee of the Radiation Therapy Oncology Group (RTOG). He is also a member of the board of directors of the International Association for the Study of Lung Cancer (IASLC). He is a member of the board of directors of UT Southwestern Health Systems and sits on several other institutional committees. He is a member of the editorial board of Cancer Research and Treatment, Clinical Lung Cancer and other scientific publications, and has served as reviewer for the New England Journal of Medicine and many others. Dr. Choy holds a patent for the radio-enhanced delivery of camptothecin-derivative drugs for cancer treatment.